ACSL4 is a predictive biomarker of sorafenib sensitivity in hepatocellular carcinoma

Sorafenib is the first-line treatment of advanced hepatocellular carcinoma (HCC). However, there is a lack of validated biomarkers to predict sorafenib sensitivity. In this study we investigated the role of ACSL4, a positive-activating enzyme of ferroptosis, in sorafenib-induced cell death and HCC p...

Full description

Saved in:
Bibliographic Details
Published in:Acta pharmacologica Sinica 2021-01, Vol.42 (1), p.160-170
Main Authors: Feng, Ji, Lu, Pei-zhi, Zhu, Guang-zhi, Hooi, Shing Chung, Wu, Yong, Huang, Xiao-wei, Dai, Hui-qi, Chen, Pan-hong, Li, Zhong-jie, Su, Wen-jing, Han, Chuang-ye, Ye, Xin-ping, Peng, Tao, Zhou, Jing, Lu, Guo-dong
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - therapeutic use
Biomarkers
Biomarkers, Tumor - metabolism
Biomedical and Life Sciences
Biomedicine
Carcinoma, Hepatocellular - diagnosis
Carcinoma, Hepatocellular - drug therapy
Carcinoma, Hepatocellular - metabolism
Carcinoma, Hepatocellular - pathology
Cell death
Cell Line, Tumor
Coenzyme A Ligases - genetics
Coenzyme A Ligases - metabolism
Ferroptosis
Ferroptosis - drug effects
Gene Knockout Techniques
Hepatocellular carcinoma
Humans
Immunology
Inhibitor drugs
Internal Medicine
Lipid peroxidation
Liver cancer
Liver Neoplasms - diagnosis
Liver Neoplasms - drug therapy
Liver Neoplasms - metabolism
Liver Neoplasms - pathology
Male
Medical Microbiology
Mice
Mice, Inbred BALB C
Patients
Pharmacology/Toxicology
Prognosis
siRNA
Sorafenib - therapeutic use
Surgery
Targeted cancer therapy
Vaccine
Xenograft Model Antitumor Assays
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!